Financial incentives for smoking cessation in pregnancy: multicentre randomised controlled trial

Ivan Berlin, Noémi Berlin, Marie Malecot, Martine Breton, Florence Jusot, Léontine Goldzahl, Ivan Berlin, Noémi Berlin, Marie Malecot, Martine Breton, Florence Jusot, Léontine Goldzahl

Abstract

Objective: To evaluate the efficacy of financial incentives dependent on continuous smoking abstinence on smoking cessation and birth outcomes among pregnant smokers.

Design: Single blind, randomised controlled trial.

Setting: Financial Incentive for Smoking Cessation in Pregnancy (FISCP) trial in 18 maternity wards in France.

Participants: 460 pregnant smokers aged at least 18 years who smoked ≤5 cigarettes/day or ≤3 roll-your-own cigarettes/day and had a pregnancy gestation of <18 weeks were randomised to a financial incentives group (n=231) or a control group (n=229).

Interventions: Participants in the financial incentives group received a voucher equivalent to €20 (£17; $23), and further progressively increasing vouchers at each study visit if they remained abstinent. Participants in the control group received no financial incentive for abstinence. All participants received a €20 show-up fee at each of six visits.

Main outcome measures: The main outcome measure was continuous smoking abstinence from the first post-quit date visit to visit 6, before delivery. Secondary outcomes in the mothers were point prevalence abstinence, time to smoking relapse, withdrawal symptoms, blood pressure, and alcohol and cannabis use in past 30 days. Secondary outcomes in the babies were gestational age at birth, birth characteristics (birth weight, length, head circumference, Apgar score), and a poor neonatal outcome-a composite measure of transfer to the neonatal unit, congenital malformation, convulsions, or perinatal death.

Results: Mean age was 29 years. In the financial incentives and control groups, respectively, 137 (59%) and 148 (65%) were employed, 163 (71%) and 171 (75%) were in a relationship, and 41 (18%) and 31 (13%) were married. The participants had smoked a median of 60 cigarettes in the past seven days. The continuous abstinence rate was significantly higher in the financial incentives group (16%, 38/231) than control group (7%, 17/229): odds ratio 2.45 (95% confidence interval 1.34 to 4.49), P=0.004). The point prevalence abstinence rate was higher (4.61, 1.41 to 15.01, P=0.011), the median time to relapse was longer (visit 5 (interquartile range 3-6) and visit 4 (3-6), P<0.001)), and craving for tobacco was lower (β=-1.81, 95% confidence interval -3.55 to -0.08, P=0.04) in the financial incentives group than control group. Financial incentives were associated with a 7% reduction in the risk of a poor neonatal outcome: 4 babies (2%) in the financial incentives group and 18 babies (9%) in the control group: mean difference 14 (95% confidence interval 5 to 23), P=0.003. Post hoc analyses suggested that more babies in the financial incentives group had birth weights ≥2500 g than in the control group: unadjusted odds ratio 1.95 (95% confidence interval 0.99 to 3.85), P=0.055; sex adjusted odds ratio 2.05 (1.03 to 4.10), P=0.041; and sex and prematurity adjusted odds ratio 2.06 (0.90 to 4.71), P=0.086. As these are post hoc analyses, the results should be interpreted with caution.

Conclusions: Financial incentives to reward smoking abstinence compared with no financial incentives were associated with an increased abstinence rate in pregnant smokers. Financial incentives dependent on smoking abstinence could be implemented as a safe and effective intervention to help pregnant smokers quit smoking.

Trial registration: ClinicalTrials.gov NCT02606227.

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: no support from the French National Cancer Institute (INCa); no support from any organisation for the submitted work with the exception of LG who was supported by the study’s grant and by a grant from the health chair—a joint initiative between Paris Sciences et Lettres (PSL), Université Paris-Dauphine, l’École nationale de la statistique et de l’administration économique (ENSAE), Mutuelle générale de l’Éducation nationale (MGEN), Université Paris-Dauphine, and ISTYA Collectives under the aegis of the Fondation du Risque as a postdoctoral fellow. All authors declare no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Fig 1
Fig 1
Pay-off tree showing what participants could earn according to group assignment and smoking abstinence status under the assumption that they completed six visits. At the first visit, participants were randomised to either the financial incentives group or the control group if they agreed to take part in the study. All participants received a €20 (£17; $23) voucher at the end of the randomisation visit. A=abstinent; NA=not abstinent
Fig 2
Fig 2
Flow of pregnant smokers and their offspring through the study
Fig 3
Fig 3
Point prevalence smoking abstinence rate by visit. Mixed effects logistic model: odds ratio 4.61 (95% confidence interval 1.41 to 15.01), P=0.011. Whiskers represent 95% confidence intervals
Fig 4
Fig 4
Time to lapse or relapse to first cigarette (log rank test, P

Fig 5

12 item French Tobacco Craving…

Fig 5

12 item French Tobacco Craving Questionnaire. Mixed effects linear model: β= −1.81 (95%…

Fig 5
12 item French Tobacco Craving Questionnaire. Mixed effects linear model: β= −1.81 (95% confidence interval −3.55 to −0.08), P=0.040. Whiskers represent 95% confidence intervals
Fig 5
Fig 5
12 item French Tobacco Craving Questionnaire. Mixed effects linear model: β= −1.81 (95% confidence interval −3.55 to −0.08), P=0.040. Whiskers represent 95% confidence intervals

References

    1. National Centre for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health . The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Centers for Disease Control and Prevention, 2014.
    1. US Centres for Disease Control and Prevention, U.S. Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. CDC, 2006.
    1. Grangé G, Berlin I, Bretelle F, et al. . Smoking and smoking cessation in pregnancy. Synthesis of a systematic review. J Gynecol Obstet Hum Reprod 2020;49:101847. 10.1016/j.jogoh.2020.101847.
    1. Tobacco and Nicotine Cessation During Pregnancy: ACOG Committee Opinion. Number 807. Obstet Gynecol 2020;135:e221-9. 10.1097/AOG.0000000000003822.
    1. US Preventive Services Task Force . Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement. JAMA 2021;19:265-79. 10.1001/jama.2020.25019.
    1. Claire R, Chamberlain C, Davey MA, et al. . Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2020;3:CD010078. 10.1002/14651858.CD010078.pub3.
    1. Higgins ST, Heil SH, Solomon LJ, et al. . A pilot study on voucher-based incentives to promote abstinence from cigarette smoking during pregnancy and postpartum. Nicotine Tob Res 2004;6:1015-20. 10.1080/14622200412331324910.
    1. Heil SH, Higgins ST, Bernstein IM, et al. . Effects of voucher-based incentives on abstinence from cigarette smoking and fetal growth among pregnant women. Addiction 2008;103:1009-18. 10.1111/j.1360-0443.2008.02237.x.
    1. Higgins ST, Bernstein IM, Washio Y, et al. . Effects of smoking cessation with voucher-based contingency management on birth outcomes. Addiction 2010;105:2023-30. 10.1111/j.1360-0443.2010.03073.x.
    1. Higgins ST, Washio Y, Heil SH, et al. . Financial incentives for smoking cessation among pregnant and newly postpartum women. Prev Med 2012;55(Suppl):S33-40. 10.1016/j.ypmed.2011.12.016.
    1. Higgins ST, Washio Y, Lopez AA, et al. . Examining two different schedules of financial incentives for smoking cessation among pregnant women. Prev Med 2014;68:51-7. 10.1016/j.ypmed.2014.03.024.
    1. Ondersma SJ, Svikis DS, Lam PK, Connors-Burge VS, Ledgerwood DM, Hopper JA. A randomized trial of computer-delivered brief intervention and low-intensity contingency management for smoking during pregnancy. Nicotine Tob Res 2012;14:351-60. 10.1093/ntr/ntr221.
    1. Tappin D, Bauld L, Purves D, et al. Cessation in Pregnancy Incentives Trial Team . Financial incentives for smoking cessation in pregnancy: randomised controlled trial. BMJ 2015;350:h134. 10.1136/bmj.h134.
    1. Berlin N, Goldzahl L, Jusot F, Berlin I. Protocol for study of financial incentives for smoking cessation in pregnancy (FISCP): randomised, multicentre study. BMJ Open 2016;6:e011669. 10.1136/bmjopen-2016-011669.
    1. Conférence de consensus . “grossesse et tabac” : texte des recommandations. Prof Sage-Femme 2005;(112):19-34.
    1. Grossesse et arrêt du tabac : Accompagner par l’écoute et le dialogue - Les essentiels de l’Inpes - Essentiel_GrossesseArretTabac.pdf. Accessed February 15, 2016.
    1. SRNT Subcommittee on Biochemical Verification . Biochemical verification of tobacco use and cessation. Nicotine Tob Res 2002;4:149-59. 10.1080/14622200210123581.
    1. Berlin I, Singleton EG, Heishman SJ. Validity of the 12-item French version of the Tobacco Craving Questionnaire in treatment-seeking smokers. Nicotine Tob Res 2010;12:500-7. 10.1093/ntr/ntq039.
    1. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986;43:289-94. 10.1001/archpsyc.1986.01800030107013.
    1. Taylor L, Claire R, Campbell K, et al. . Fetal safety of nicotine replacement therapy in pregnancy: systematic review and meta-analysis. Addiction 2021;116:239-77. 10.1111/add.15185.
    1. Weise A. WHA Global Nutrition Targets 2025: Low Birth Weight Policy Brief. WHO Publ. Published online 2012:1-7.
    1. Born too soon: the global action report on preterm birth. 2012.
    1. Berlin N, Goldzahl L, Bauld L, Hoddinott P, Berlin I. Public acceptability of financial incentives to reward pregnant smokers who quit smoking: a United Kingdom-France comparison. Eur J Health Econ 2018;19:697-708. 10.1007/s10198-017-0914-6.
    1. Notley C, Gentry S, Livingstone-Banks J, Bauld L, Perera R, Hartmann-Boyce J. Incentives for smoking cessation. Cochrane Database Syst Rev 2019;7:CD004307. 10.1002/14651858.CD004307.pub6.
    1. Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob Res 2012;14:75-8. 10.1093/ntr/ntr137.
    1. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA 1984;252:1905-7. 10.1001/jama.1984.03350140051025

Source: PubMed

3
订阅